Premium
EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB
Author(s) -
Dreyling M.,
Santoro A.,
Leppä S.,
Demeter J.,
Follows G.A.,
Lenz G.,
Kim W.S.,
Mollica L.,
Nagler A.,
Phipps Diong C.,
Provencio M.,
Magagnoli M.,
Munoz J.,
Hiemeyer F.,
Liu L.,
Miriyala A.,
Rodrigues L.,
GarciaVargas J.,
Childs B.H.,
Zinzani P.L.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.57_2631
Subject(s) - medicine , follicular lymphoma , bendamustine , clinical endpoint , gastroenterology , regimen , refractory (planetary science) , adverse effect , neutropenia , rituximab , lymphoma , oncology , chemotherapy , clinical trial , biology , astrobiology